GSK has halted all shipments of ARIXTRA Starter Kits containing the Triad For important product information, log onto Arixtra mg/ ml solution for injection, pre-filled syringe. 2. .. Detailed information on this medicinal product is available on the website of the European . Arixtra is a medicine that helps prevent blood clots from forming in the blood This medicinal product contains less than 23 mg of sodium in each dose and.
|Published (Last):||5 September 2012|
|PDF File Size:||16.3 Mb|
|ePub File Size:||10.51 Mb|
|Price:||Free* [*Free Regsitration Required]|
Arixtra Monograph for Professionals –
Insert the entire length of the needle into a skin fold created by the thumb and forefinger; hold the skin fold, and push the plunger of the syringe the full length of the syringe barrel. To view content sources and attributions, please refer to our editorial policy. Used in conjunction with warfarin for treatment of DVT and acute PE when initial therapy is administered in the hospital.
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: Usual duration of therapy is 5—9 days, although up to 10 days has been studied. Research Triangle Park, NC: The easiest way to lookup drug information, identify pills, check interactions and set prescribinf your own personal medication records.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip- fracture surgery. Distributed into milk in rats; not known whether distributed into human milk. Some packaging components e. Active major bleeding, bacterial endocarditis, or thrombocytopenia associated with a prewcribing in vitro test for antiplatelet antibody HIT in the presence of the drug.
Clin Appl Thromb Hemost. Increased risk of hemorrhage; closely monitor for signs and symptoms of bleeding.
Prevention of VTE in nonsurgical patients: Used in patients undergoing PCI to prevent thrombus formation during the procedure; however, should not be used as the sole anticoagulant to support PCI. No specific dosage recommendations; however, careful attention to dosage directions recommended. Platelet function or global clotting function tests e. We comply with prescrribing HONcode standard for trustworthy health information – verify here.
Importance of discontinuing fondaparinux and immediately contacting a clinician if a serious allergic reaction e. Lovenox enoxaparin sodium injection prescribing information. The activity of fondaparinux xrixtra is measured based on plasma drug concentrations quantified by anti-factor Xa activity using fondaparinux as the calibrator. Importance of advising patients who have had neuraxial anesthesia or spinal puncture to monitor for manifestations of spinal or epidural hematoma e.
Following a single 7. ACCP recommends fondaparinux as an option for thromboprophylaxis in acutely ill, hospitalized medical patients at increased risk of thrombosis. Efficacy and safety of fondaparinux informaton enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
In general, pharmacologic thromboprophylaxis is recommended only in such patients considered to be at high risk of venous thromboembolism. Patients should be sitting or supine during administration. No dosage adjustment required in patients with mild to moderate hepatic impairment.
VTE, thrombophilia, antithrombotic therapy, and pregnancy: Available for Android and iOS devices. Medically reviewed on Oct 23, Prevention of VTE in nonorthopedic surgical patients: A randomized double-blind comparison. If PCI is performed arixtta a patient is receiving fondaparinux, administer an additional anticoagulant with anti-factor IIa antithrombin activity because of the risk of catheter thrombosis.
Risk also increased by history of traumatic or repeated epidural or spinal puncture, spinal deformity, or spinal surgery. Treatment and prevention of heparin-induced thrombocytopenia: Bounameaux, H, Perneger T.